Literature DB >> 10583697

Clinically significant pharmacokinetic drug interactions with benzodiazepines.

E Tanaka1.   

Abstract

The reports of interactions between benzodiazepines (BZPs) and other drugs (e.g., antidepressants, selective serotonin reuptake inhibitors, antiulcer drugs, antiepileptic drugs, macrolide antibiotics) during their combined use are reviewed. In general, metabolism of BZPs is delayed when combined with a number of other drugs but some reports have suggested otherwise. In recent years, the cytochrome P450 (P450 or CYP) isoenzyme that catalyses the metabolism of BZPs has also been identified. BZPs are mainly catalysed by CYP3A4. When published reports are studied, it appears necessary to be exceptionally careful about interactions mainly between BZPs and selective serotonin reuptake inhibitors, cimetidine, antiepileptic drugs, macrolide antibiotics and antimycotics. More information is necessary to identify individuals at greatest risk of drug interactions and adverse events.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10583697     DOI: 10.1046/j.1365-2710.1999.00247.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  3 in total

1.  Clinically significant psychotropic drug-drug interactions in the primary care setting.

Authors:  Brett A English; Marcus Dortch; Larry Ereshefsky; Stanford Jhee
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

2.  Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy.

Authors:  Isabelle Ragueneau-Majlessi; Rene H Levy; Martin Brodie; David Smith; Jaymin Shah; John S Grundy
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Insomnia in general practice : a consensus report produced by sleep specialists and primary-care physicians in Italy.

Authors:  Mario Giovanni Terzano; Liborio Parrino; Enrica Bonanni; Fabio Cirignotta; Franco Ferrillo; Gian Luigi Gigli; Mariantonietta Savarese; Luigi Ferini-Strambi
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.